Steven M. Albelda

faculty photo
William Maul Measey Professor of Medicine
Member, Penn Cancer Center
Co-Director, Thoracic Oncology Research Laboratory, University of Pennsylvania
Director of Lung Research, Pulmonary, Allergy, and Critical Care, University of Pennsylvania
Vice Chief, Pulmonary and Critical Care, University of Pennsylvania
Founding Member, Center for Cancer Pharmacology
Co-Director. Translational Center of Excellence in Lung Cancer, Abramson Cancer Center
Department: Medicine

Contact information
228 Stemmler Hall
3450 Hamilton Walk
Philadelphia, PA 19104-6118
Office: (215) 573-9933
Fax: (215) 746-0376
Graduate Group Affiliations
B.A. (Chemistry)
Williams College, 1975.
University of Pennsylvania, 1979.
Permanent link

Description of Research Expertise

Immuno-gene Therapy for Thoracic Malignancies
Lung cancer and other thoracic malignancies are the leading cause of cancer deaths in the United States today. The Thoracic Oncology Research Laboratory is focusing on the design of new treatment strategies for lung cancer and mesothelioma based on the rapidly evolving disciplines of molecular biology, immunotherapy, and gene therapy.
Dr. Albelda’s research is translational in focus and includes animal models, work with human tumor samples, and the conduct of clinical trials. This work is primarily funded through a recently renewed Program Project from the National Cancer Institute and participation in a number of RO1 grants.
The tumor microenvironment is one area of active study. Studies are underway with the goals of 1) a better understanding of the biology of the tumor microenvironment with a focus on the immunuosuppressive activities of white blood cells and fibroblasts, 2) novel approaches to alter the tumor microenvironment to enhance immunotherapy including studying effects using COX-2 inhibitors, TGFbeta inhibitors, T-regulatory cell inhibitors., antibodies against B-cells, and chemotherapeutic drugs. A second area of interest in the lab is the use of adoptive T cell transfer to treat lung malignancies. Studies are underway to modify T cells in order to make them traffic more efficiently into tumors, to have better killing function, and to resist inactivation by the tumor microenvironment. A T cells targeting cancer-associated fibroblasts is being developed. In addition, Dr. Albelda is closely involved with a number of immunogene clinical trials at Penn using an adenovirus expressing the immune-activator interferon-alpha that is instilled into the pleural space of mesothelioma patients (in collaboration with Dr. Daniel Sterman) and T cells altered to attack the mesothelioma tumor target, mesothelin (in collaboration with Drs. Carl June and Andrew Haas).

Description of Itmat Expertise

Dr. Albelda's lab is interested in translational approaches to lung cancer and mesothelioma. Preclinical studies evaluate new treatments in animal models, genetic and genomic studies using human blood and cancer tissue samples, and clinical trials of novel therapeutics.

Selected Publications

Chen Xiao, Yang Yizeng, Berger Ian, Khalid Urooj, Patel Akash, Cai Jenny, Farwell Michael D, Langer Corey, Aggarwal Charu, Albelda Steven M, Katz Sharyn I: Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. Oncotarget Page: Epub ahead of print, Sep 2016.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan D, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner L, Cengel KA, Simone CB, Culligan M, Langer C, Albelda SM: Pilot and Feasibility Trial of Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-Interferon-alpha Combined with Chemotherapy. Clinical Cancer Research 22(15): 3791-3800, August 2016 Notes: doi: 10.1158/1078-0432.CCR-15-2133.

Singhal Sunil, Bhojnagarwala Pratik S, O'Brien Shaun, Moon Edmund K, Garfall Alfred L, Rao Abhishek S, Quatromoni Jon G, Stephen Tom Li, Litzky Leslie, Deshpande Charuhas, Feldman Michael D, Hancock Wayne W, Conejo-Garcia Jose R, Albelda Steven M, Eruslanov Evgeniy B: Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. Cancer cell 30(1): 120-35, Jul 2016.

Newick Kheng, O'Brien Shaun, Sun Jing, Kapoor Veena, Maceyko Steven, Lo Albert, Pure Ellen, Moon Edmund K, Albelda Steven M: Augmentation of CAR T cell trafficking and antitumor efficacy by blocking protein kinase A (PKA) localization. Cancer immunology research 4(6): 541-51, June 2016 Notes: doi: 10.1158/2326-6066.CIR-15-0263.

Newick K, Moon E, Albelda SM: Chimeric Antigen Receptor T Cell Therapy for Solid Tumors. Molecular Therapy Oncolytics 3: 16006, April 2016 Notes: doi: 10.1038/mto.2016.6.

Pietrofesa Ralph A, Velalopoulou Anastasia, Albelda Steven M, Christofidou-Solomidou Melpo: Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605). International journal of molecular sciences 17(3): 322, March 2016 Notes: doi: 10.3390/ijms17030322.

Pietrofesa Ralph A, Velalopoulou Anastasia, Arguiri Evguenia, Menges Craig W, Testa Joseph R, Hwang Wei-Ting, Albelda Steven M, Christofidou-Solomidou Melpo: Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis 37(2): 177-87, Feb 2016.

Moon Edmund K, Ranganathan Raghuveer, Eruslanov Evgeniy, Kim Soyeon, Newick Kheng, O'Brien Shaun, Lo Albert, Liu Xiaojun, Zhao Yangbing, Albelda Steven M: Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clinical Cancer Research : an official journal of the American Association for Cancer Research 22(2): 436-47, Jan 2016.

Hubaux Roland, Vandermeers Fabian, Cosse Jean-Philippe, Crisanti Cecilia, Kapoor Veena, Albelda Steven M, Mascaux Céline, Delvenne Philippe, Hubert Pascale, Willems Luc: Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models. ERJ open research 1(2): pii: 00028-2015, Oct 2015.

Kennedy Gregory T, Okusanya Olugbenga T, Keating Jane J, Heitjan Daniel F, Deshpande Charuhas, Litzky Leslie A, Albelda Steven M, Drebin Jeffrey A, Nie Shuming, Low Philip S, Singhal Sunil: The Optical Biopsy: A Novel Technique for Rapid Intraoperative Diagnosis of Primary Pulmonary Adenocarcinomas. Annals of surgery 262(4): 602-9, Oct 2015.

back to top
Last updated: 10/20/2016
The Trustees of the University of Pennsylvania